EMBC
Price
$3.19
Change
-$0.18 (-5.34%)
Updated
Jul 8 closing price
Capitalization
189.85M
29 days until earnings call
Intraday BUY SELL Signals
WAT
Price
$368.13
Change
-$6.80 (-1.81%)
Updated
Jul 8 closing price
Capitalization
36.15B
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EMBC vs WAT

EMBC vs WAT Comparison Chart in %
View a ticker or compare two or three
VS
EMBC vs. WAT commentary
Jul 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EMBC is a Hold and WAT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2026
Stock price -- (EMBC: $3.37 vs. WAT: $368.13)
Brand notoriety: EMBC and WAT are both not notable
EMBC represents the Pharmaceuticals: Other, while WAT is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EMBC: 50% vs. WAT: 77%
Market capitalization -- EMBC: $189.85M vs. WAT: $36.15B
EMBC [@Pharmaceuticals: Other] is valued at $189.85M. WAT’s [@Medical Specialties] market capitalization is $36.15B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $151.33B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $8.13B. The average market capitalization across the [@Medical Specialties] industry is $16.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EMBC’s FA Score shows that 2 FA rating(s) are green whileWAT’s FA Score has 1 green FA rating(s).

  • EMBC’s FA Score: 2 green, 3 red.
  • WAT’s FA Score: 1 green, 4 red.
According to our system of comparison, both EMBC and WAT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EMBC’s TA Score shows that 3 TA indicator(s) are bullish while WAT’s TA Score has 4 bullish TA indicator(s).

  • EMBC’s TA Score: 3 bullish, 4 bearish.
  • WAT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EMBC is a better buy in the short-term than WAT.

Price Growth

EMBC (@Pharmaceuticals: Other) experienced а +0.30% price change this week, while WAT (@Medical Specialties) price change was -2.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.80%. For the same industry, the average monthly price growth was +10.25%, and the average quarterly price growth was -8.71%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.80%. For the same industry, the average monthly price growth was +10.52%, and the average quarterly price growth was +5.71%.

Reported Earning Dates

EMBC is expected to report earnings on Aug 07, 2026.

WAT is expected to report earnings on Aug 04, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (+0.80% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (-2.80% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WAT($36.1B) has a higher market cap than EMBC($190M). WAT has higher P/E ratio than EMBC: WAT (46.84) vs EMBC (1.69). WAT YTD gains are higher at: -3.080 vs. EMBC (-71.133). WAT has higher annual earnings (EBITDA): 991M vs. EMBC (312M). WAT has more cash in the bank: 462M vs. EMBC (185M). EMBC has less debt than WAT: EMBC (1.36B) vs WAT (5.57B). WAT has higher revenues than EMBC: WAT (3.77B) vs EMBC (1.04B).
EMBCWATEMBC / WAT
Capitalization190M36.1B1%
EBITDA312M991M31%
Gain YTD-71.133-3.0802,309%
P/E Ratio1.6946.844%
Revenue1.04B3.77B28%
Total Cash185M462M40%
Total Debt1.36B5.57B24%
FUNDAMENTALS RATINGS
WAT: Fundamental Ratings
WAT
OUTLOOK RATING
1..100
8
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
84
SMR RATING
1..100
85
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
19
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EMBCWAT
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
65%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
65%
Advances
ODDS (%)
Bullish Trend 14 days ago
75%
Bullish Trend 8 days ago
63%
Declines
ODDS (%)
Bearish Trend 29 days ago
83%
Bearish Trend 1 day ago
64%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
63%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
EMBC
Daily Signal:
Gain/Loss:
WAT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SECEX26.00N/A
N/A
NAA Large Core A
STPCX10.36N/A
N/A
Saratoga Technology & Comm C
SCIJX23.54N/A
N/A
Hartford Schroders International Stk SDR
INKDX11.10N/A
N/A
Victory Pioneer Disciplined Growth R6
DDDRX16.89-0.04
-0.24%
Nomura Wealth Builder R

EMBC and

Correlation & Price change

A.I.dvisor indicates that over the last year, EMBC has been loosely correlated with BLFS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EMBC jumps, then BLFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EMBC
1D Price
Change %
EMBC100%
N/A
BLFS - EMBC
43%
Loosely correlated
N/A
WAT - EMBC
37%
Loosely correlated
-1.81%
MTD - EMBC
37%
Loosely correlated
-3.60%
AVTR - EMBC
37%
Loosely correlated
-4.31%
RVTY - EMBC
36%
Loosely correlated
-2.41%
More